Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austco HealthcareASX:AHC 63 3-Year EPS without NRI Growth Rate is 44.20% as of Jun. 2026, which is 83% above its 10-year median of 24.20. GuruFocus rates ASX:AHC with a GF Score™ of 63/100 and a GF Value™ of A$0.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 662 Medical Devices & Instruments companies, Austco Healthcare ranks better than 85.05% on this metric.
During the past 12 months, Austco Healthcare's average EPS without NRI Growth Rate was 50.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 44.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 20.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Austco Healthcare was 51.80% per year. The lowest was -40.00% per year. And the median was 24.20% per year.
Austco Healthcare (ASX:AHC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Austco Healthcare 3-Year EPS without NRI Growth Rate Related Terms
ASX:AHC vs ISRG, BDX, RMD: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Austco Healthcare's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austco Healthcare 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austco Healthcare's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Austco Healthcare's 3-Year EPS without NRI Growth Rate falls into.
Austco Healthcare 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 44.20% mean?
Austco Healthcare (ASX:AHC) has a 3-Year EPS without NRI Growth Rate of 44.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Austco Healthcare and its competitors. This is 83% above median its historical median of 24.20. According to the industry distribution chart, Austco Healthcare ranks #99 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 15%.
Is Austco Healthcare's 3-Year EPS without NRI Growth Rate too high?
Austco Healthcare's current 3-Year EPS without NRI Growth Rate of 44.20% is 83% above median its 10-year median of 24.20. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Austco Healthcare's value of 44.20% is 449.1% above this industry median. Based on the distribution chart, Austco Healthcare ranks #99 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austco Healthcare has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Austco Healthcare's 3-Year EPS without NRI Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Austco Healthcare ranks #99 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Austco Healthcare in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Austco Healthcare's value of 44.20% is 449.1% above this benchmark. While the company's 10-year median is 24.20 vs. the industry median of 8.05, Austco Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austco Healthcare's current 3-Year EPS without NRI Growth Rate of 44.20% is 449.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Austco Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austco Healthcare's current 3-Year EPS without NRI Growth Rate is 44.20%, which is 83% above median its own 10-year median of 24.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austco Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Austco Healthcare (ASX:AHC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.34, compared to a current price of A$0.27 — trading 20.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 44.20%, which is 83% above median its 10-year median of 24.20 and 449.1% above the Medical Devices & Instruments industry median of 8.05. Austco Healthcare's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Austco Healthcare (ASX:AHC), the current 3-Year EPS without NRI Growth Rate is 44.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austco Healthcare (ASX:AHC) Overvalued in 2026?
Based on GuruFocus' analysis, Austco Healthcare stock appears to be undervalued.
The current stock price of A$0.27 is trading 20.6% below its estimated GF Value™ of A$0.34.
GuruFocus considers Austco Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:AHC:
3-Year EPS without NRI Growth Rate: 44.20% (83% above median its 10-year median of 24.20)
GF Value™: A$0.34 vs. price of A$0.27 (20.6% below fair value)
Industry Position: 449.1% above the Medical Devices & Instruments median (#99 of 662)
No single metric tells the full story. See the ASX:AHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austco Healthcare Ltd engages in the development and provision of electronic communications and clinical management solutions. It offers Tacera, a nurse call, and healthcare communication system for healthcare professionals and patient. The group is segmented into four geographic regions consisting of Australia/New Zealand, Asia, Europe, and North America.
63GF Score
Get the complete analysis for ASX:AHC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AHC has been successfully added to your 
